MSB

1.02%

99.0¢ mesoblast limited

Ann: FDA Supports Accelerated Approval Pathway for Heart Failure, page-430

First 430 Last

Share
Profile

Follow
DocMcstuffins

7,771 Posts.

1337

18/03/24

09:47

Post #: 72934398
Share

Originally posted by Leo65: ↑

With an appropriate post hoc statistical test we can reduce the risk of type I error (this error is inflated in multiple comparison between several subgroups) and also obtain acceptable statistical power, which of course depends on the sample size and data variance in subgroups. Brief, choosing an appropriate multi comparison test and having high number of data points in subgroups and low variance make the post hoc statistical analysis scientifically valid.

I found below a good summary of what we need to consider in post hoc analysis. In our case showing cells are more efficient in treatment of patients with higher inflammation (e.g, higher IL-6) is highly plausible and correlated with the proposed mechanism of action.

“Reporting of treatment effects on subgroups of patients are common in the medical literature. Although knowing how well a new treatment works in patients with a specific biomarker or a specific combination of disease stage and histology are important for the patients and their clinicians to make informed treatment decisions, it is important to be cautious when interpreting the results of subgroup analyses. Common challenges with subgroup analyses include poor definitions, low statistical power, and inflated type I error due to multiple hypotheses testing. The decision to conduct a subgroup analysis should depend biological justification or on evidence of treatment heterogeneity from existing preliminary data. When a large number of unplanned subgroup analyses are conducted, the treatment may spuriously appear to be effective in one or more subgroups. One should always assess the validity of subgroup analysis results based on biological plausibility, sample size for the subgroup, proper type I error control and power.”

Expand

I'm not saying the cells don't work.

I'm saying they havent been properly proven to work. They've generated hypotheses, but they haven't confirmed any of them with an independent RCT.

And it's a bit concerning they only seem to get significant results when they are analysing subgroups - if they managed to do an RCT that met its primary endpoint things would be looking much better.

Last edited by DocMcstuffins: 18/03/24

MSB Price at posting: 35.5¢ Sentiment: Sell Disclosure: Not Held
3 Upvote

0 Great analysis

Reply

Top Stories

LRV

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom

3DP

Pointerra wins US$1.63M from US Dept of Energy to model climate change scenarios

CMX

ChemX Materials kicks off first stage works at WA high purity alumina pilot

SVL

Silver Mines models five new calderas close to 396Moz Bowdens deposit

SS1

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

LU7

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

AVA

Ava Risk Group expands US presence with A$0.7M Substation Deal

RCE

Recce's R327 found effective against E.coli during clinical trial

Microcap Wrap: 5 explorers with news out today

There are more pages in this discussion • 120 more messages in this thread...

First 430 Last

Add MSB (ASX) to my watchlist

(20min delay)
Last 99.0¢		Change 0.010(1.02%)		Mkt cap ! $1.130B

Open	High	Low	Value	Volume
99.5¢	$1.02	98.5¢	$5.507M	5.501M

Buyers (Bids)

No.	Vol.	Price($)
1	9996	99.0¢

Sellers (Offers)

Price($)	Vol.	No.
99.5¢	18069	3

View Market Depth

No.	Vol.	Price($)
1	9996	0.990
2	32880	0.985
7	256748	0.980
3	27201	0.975
8	170032	0.970

Price($)	Vol.	No.
0.995	18069	3
1.000	26186	7
1.005	72373	3
1.010	82743	7
1.015	72242	5

Last trade - 16.10pm 28/06/2024 (20 minute delay)

MSB (ASX) Chart

Ann: FDA Supports Accelerated Approval Pathway for Heart Failure, page-430

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom

Pointerra wins US$1.63M from US Dept of Energy to model climate change scenarios

ChemX Materials kicks off first stage works at WA high purity alumina pilot

Silver Mines models five new calderas close to 396Moz Bowdens deposit

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

Ava Risk Group expands US presence with A$0.7M Substation Deal

Recce's R327 found effective against E.coli during clinical trial

Microcap Wrap: 5 explorers with news out today

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: FDA Supports Accelerated Approval Pathway for Heart Failure, page-430

Top Stories

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom

Pointerra wins US$1.63M from US Dept of Energy to model climate change scenarios

ChemX Materials kicks off first stage works at WA high purity alumina pilot

Silver Mines models five new calderas close to 396Moz Bowdens deposit

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

Ava Risk Group expands US presence with A$0.7M Substation Deal

Recce's R327 found effective against E.coli during clinical trial

Microcap Wrap: 5 explorers with news out today

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News